Mycoplasma hyopneumoniae bacterin vaccine

Details Mycoplasma hyopneumoniae bacterin vaccine Mycoplasma hyopneumoniae bacterin vaccine

2006-08-21

2010-02-23

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S203100, C424S234100, C424S093400, C424S093100, C424S825000

Reexamination Certificate

active

07666439

ABSTRACT:
The invention provides an improvedMycoplasma hyopneumoniaebacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedMycoplasma hyopneumoniaebacterin and an adjuvant mixture, which, in combination, provide immunity fromMycoplasma hyopneumoniaeinfection after a single administration, and elicit an immune response specific toMycoplasma hyopneumoniaebacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

REFERENCES:
patent: 2909462 (1959-10-01), Warfield et al.
patent: 3790665 (1974-02-01), Glass et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 5080896 (1992-01-01), Visser et al.
patent: 5240706 (1993-08-01), Faulds
patent: 5338543 (1994-08-01), Fitzgerald et al.
patent: 5534256 (1996-07-01), Potter et al.
patent: 5565205 (1996-10-01), Petersen et al.
patent: 5695769 (1997-12-01), Frantz et al.
patent: 5846735 (1998-12-01), Stapleton et al.
patent: 6113916 (2000-09-01), Bhogal et al.
patent: 6193971 (2001-02-01), Hofmann et al.
patent: 6342231 (2002-01-01), Burkhardt et al.
patent: 6585981 (2003-07-01), Pijoan
patent: 6753417 (2004-06-01), Hansen et al.
patent: 6846477 (2005-01-01), Keich et al.
patent: 7018638 (2006-03-01), Chu et al.
patent: 7169394 (2007-01-01), Chu et al.
patent: 2002/0114817 (2002-08-01), Liem et al.
patent: 0 283 085 (1988-09-01), None
patent: 0 315 153 (1989-05-01), None
patent: WO 91/18627 (1991-12-01), None
patent: WO 92/03157 (1992-03-01), None
patent: WO 93/10216 (1993-05-01), None
patent: WO 95/30437 (1995-11-01), None
patent: WO 96/40268 (1996-12-01), None
patent: WO 02/10343 (2002-02-01), None
Xu et al. In: Proceedings of the 17th International Pig Veterinary Society Congress, vol. 2, p. 274, Jun. 2002.
Animal Pharm No. 422, p. 20, Jun. 4, 1999.
Merial Marketing Information on HYORESP, Jul. 15, 1998.
Pig Farming, p. 2, Jun. 1999.
Baum DH. In: Proceedings of the 16th International Pig Veterinary Society Congress, Sep. 17-21, 2000, (ed) Cargill et al. Melbourne, Australia.
Feed Stuffs 72 (30): p. 5, Jul. 17, 2000.
ASI, No. 2918, p. 2, 1999.
Alexander & Brewer, “Adjuvants and their modes of action,” Livestock Production Science, 1995, pp. 153-162, vol. 42.
Hunter et al., “The Adjuvant Activity of Nonionic Block Polymer Surfactants,” J. Immunology, Sep. 1981, pp. 1244-1250, vol. 127, No. 3.
Allison, A. C., “Squalene and Squalane Emulsions as Adjuvants,” Methods, vol. 19, pp. 87-93, 1999, Academic Press Inc., NY, NY.
Goodwin et al., “Enzootic Pneumonia of Pigs: Immunization Attempts InoculatingMycoplasma suipneumoniaeAntigen by Various Routes and with Different Adjuvants,” British Vet. J. 129(5):456-464, Sep.-Oct. 1973.
George et al.,“Route-related variation in the immunogenicity of killedSalmonella enteritidisvaccine: role of antigen presenting cell,” Microbiol. Immunol.33(6):479-488,1989.
Byars et al., “Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity,” Vaccine 5:223-228, Sep. 1987.
Martinon et al.,“Efficacy of a ‘One Shot’ Schedule of aMycoplasma hyopneumoniaeBacterin (Hyoresp),” Proc. 15th IPVS Congress, Birmingham, England, Jul. 5-9, 1998, p. 284.
Reynaud et al.,“Clinical Field Trial WithMycoplasma hyopneumoniaeBacterin (Hyoresp),” Proc. 15th IPVS Congress, Birmingham, England, Jul. 5-9, 1998, p. 150.
Charlier et al., “Comparative Efficacy of Stellamune Mycoplasma and Hyoresp in Pigs Against an Experimental Challenge withMycoplasma hyopneumoniae,” Proc. 16th IPVS Congress, Melbourne, Australia, Sep. 17-20, 2000, p. 501.

Affiliated with

Also associated with

Rating

Mycoplasma hyopneumoniae bacterin vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mycoplasma hyopneumoniae bacterin vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycoplasma hyopneumoniae bacterin vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4189316